- RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
This study, called iFIT, helps doctors find the best treatments for older myeloma patients. It checks how well standard NHS treatment works and looks at your fitness level. Then, it uses this information to decide the next steps, aiming to improve your care.
For: Multiple Myeloma (MM) · Plasma Cell Leukemia (PCL)United Kingdom - Active not recruitingPHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
This study looks at a new cell therapy called JNJ-68284528 for people with multiple myeloma. It aims to see how well it works in clearing up any remaining cancer cells after treatment.
For: Multiple MyelomaUnited States · Belgium · France - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
For: Relapsed or Refractory Multiple Myeloma (RRMM)United States · Argentina · Australia - Active not recruitingPHASE3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous therapy. It aims to see if a new combination, IberDd, works better and is safer than a standard combination, DVd, for patients in the UK.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
For: Newly Diagnosed Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
For: Multiple MyelomaGermany - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
For: Multiple MyelomaUnited States · Argentina · Belgium - Active not recruitingPHASE1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, etentamig, along with existing cancer treatments for adults with multiple myeloma that has come back or isn't responding to treatment. We want to see how safe it is and if it helps reduce the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Germany - Active not recruitingPHASE2
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
This study looks at combining two drugs, ibrutinib and daratumumab, for people with chronic lymphocytic leukemia (CLL) that has come back or not responded well to past treatments. It focuses on patients whose cancer has specific genetic changes, aiming to see if this combination works better.
For: Relapsed or Refractory Chronic Lymphocytic LeukemiaFrance - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, Cevostamab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to check its safety, how it moves in the body, and if it helps when given alone or with other medicines.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
This study looks at a new drug, ABBV-453, for multiple myeloma that has come back or not responded to previous treatments. Researchers want to see if it's safe, what side effects it might cause, and if it helps to control the disease.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Israel - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
This study looks at new drug combinations for a serious condition called AL amyloidosis, which affects the heart. We want to see how safe these treatments are for the heart and how they work in different people, especially those from diverse backgrounds.
For: AmyloidosisUnited States · Canada · China - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
For: Multiple Myeloma · Newly Diagnosed Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
For: Multiple MyelomaUnited States · Australia · Austria - Not yet recruitingPHASE2
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
This study compares two treatments, Elranatamab with Lenalidomide, and Daratumumab with Lenalidomide, for people with newly diagnosed advanced blood cancer called multiple myeloma, after they've had a stem cell transplant. It aims to see which treatment works best to keep the cancer from coming back.
For: Multiple MyelomaFrance - RecruitingPHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
This study is testing a new drug, linvoseltamab, for people with a type of blood cancer called multiple myeloma. It compares this new drug to standard treatments to see how safe and effective it is, for patients who cannot have a stem cell transplant.
For: Multiple MyelomaAustralia · Austria · Croatia - Active not recruitingPHASE1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
This study looks at new ways to treat a blood cancer called multiple myeloma. It combines an existing medicine, Daratumumab, with newer ones (Talquetamab or Teclistamab), sometimes with Pomalidomide. The main goal is to find safe doses and see how well these combinations work.
For: Multiple MyelomaUnited States · Canada · Germany - Active not recruitingPHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This study looks at new treatments for younger adults with newly diagnosed multiple myeloma. It tests combinations of medications like teclistamab and talquetamab, depending on whether a small amount of cancer is still present after initial treatment. The goal is to find better ways to manage the disease.
For: Multiple MyelomaFrance - Active not recruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
For: Multiple MyelomaUnited States · Belgium · Brazil - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
For: Relapsed and/or Refractory Multiple Myeloma (RRMM)United States · Australia · South Korea - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
This study is testing a new medicine, sonrotoclax, for people in the UK with multiple myeloma that has come back or isn't responding to treatment. Researchers want to see how safe and effective it is, both on its own and with other common myeloma drugs.
For: Relapsed/Refractory Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
This study looks at a new drug, surzetoclax, for multiple myeloma that has come back or not responded to other treatments. It checks how safe it is and how well it works, sometimes alone and sometimes with other medicines. We're looking for adults with this type of myeloma.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This study is testing a new drug called CC-220, sometimes on its own and sometimes with other standard cancer medicines, for people with multiple myeloma. It aims to find the right dose, see how safe it is, and if it helps treat the disease.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
This study looks at new drug combinations for multiple myeloma that has come back or isn’t responding to treatment. It compares a drug called talquetamab, alone or with another drug called daratumumab, against a standard treatment of daratumumab, pomalidomide, and dexamethasone.
For: Multiple MyelomaUnited States · Belgium · Brazil - Not yet recruitingPHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination (Etentamig plus Pomalidomide) with standard treatments to see if it's safe and helps improve the disease.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Canada